Woolf SH, Rothemich SF. New diabetes guidelines: a closer look at the evidence. Am Fam Physician. 1998;58(6):1287-1288.
Lazris A, Roth AR, Haskell H, et al. Prediabetes diagnosis: helpful or harmful? Am Fam Physician. 2021;104(6):649-651.
American Diabetes Association. 12. Older adults: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020;43(suppl 1):S152-S162.
Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2013(11):CD008143.
Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139.
Patel A, MacMahon S, Chalmers J, et al.; The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ. 2011;343:d6898.
Kelly TN, Bazzano LA, Fonseca VA, et al. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med. 2009;151:394-403.
Lipscombe LL, Gomes T, Lévesque LE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007;298(22):2634-2643.
Simpson SH, Majumdar SR, Tsuyuki RT, et al. Dose-response relationship between sulfonylurea drugs and mortality in type 2 diabetes: a population-based cohort study. CMAJ. 2006;174(2):169-174.
Mitka M. Aggressive glycemic control might not be the best choice for all diabetes patients. JAMA. 2010;303(12):1137-1138.
Lega LC, Campitelli MA, Austin PC, et al. Potential diabetes over-treatment and risk of adverse events among older adults in Ontario: a population-based study. Diabetologia. 2021;64(5):1093-1102.
Bruderer SG, Bodmer M, Jick SS, et al. Incidence of and risk factors for severe hypoglycaemia in treated type 2 diabetes mellitus patients in the UK—a nested case-control analysis. Diabetes Obes Metab. 2014;16(9):801-811.
Hope SV, Taylor PJ, Shields BM, et al. Are we missing hypoglycaemia? Elderly patients with insulin-treated diabetes present to primary care frequently with non-specific symptoms associated with hypoglycaemia. Prim Care Diabetes. 2018;12(2):139-146.
Lee AK, Juraschek SP, Windham BG, et al. Severe hypoglycemia and risk of falls in type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care. 2020;43(9):2060-2065.
Whitmer RA, Karter AJ, Yaffe K, et al. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301(15):1565-1572.
Yau CK, Eng C, Cenzer IS, et al. Glycosylated hemoglobin and functional decline in community-dwelling nursing home-eligible elderly adults with diabetes mellitus. J Am Geriatr Soc. 2012;60(7):1215-1221.
Martens T, Beck RW, Bailey R, et al. Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. JAMA. 2021;325(22):2262-2272.
Lin K. Are continuous glucose monitors overrated and overused? American Family Physician Community Blog, June 28, 2021. Accessed August 1, 2025. https://www.aafp.org/pubs/afp/afp-community-blog/entry/are-continuous-glucose-monitors-overrated-andoverused.html
Seidu S, Kunutsor SK, Ajjan RA, et al. Efficacy and safety of continuous glucose monitoring and intermittently scanned continuous glucose monitoring in patients with type 2 diabetes: a systematic review and meta-analysis of interventional evidence. Diabetes Care. 2024;47(1):169-179.
The patient advocacy groups that accept the most big pharma money. ClassAction.com. July 2, 2018. Accessed August 1, 2025. https://www.classaction.com/news/patient-advocacy-groups-big-pharma/
Lupkin S, Lucas E, Knight V. Big pharma gave money to patient advocacy groups opposing Medicare changes. KFF Health News. March 4, 2019. Accessed August 1, 2025. https://kffhealthnews.org/news/big-pharma-gave-money-to-patient-advocacy-groups-opposing-medicare-changes/